Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: U.S. Surgical Abbi

This article was originally published in The Gray Sheet

Executive Summary

U.S. Surgical Abbi: USSC will provide clinical data to FDA on its Abbi minimally invasive breast biopsy system in an ongoing effort to convince the agency to allow marketing of the device under its current 510(k). U.S. Surgical says it expects a "positive" outcome to the discussions and notes that it can continue selling the device pending resolution of the issue. The firm announced June 4 that FDA had indicated it may have made an error in issuing the 510(k) and was considering rescinding the premarket notification clearance ("The Gray Sheet" June 10, I&W-10). USSC also is holding discussions with the agency to resolve outstanding labeling and advertising issues regarding the Abbi system raised in a June 3 warning letter to the company...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts